A leading anti-abortion organization said it opposed moving Heidi Overton’s nomination to head the Food and Drug Administration forward unless the Trump administration made firm commitments on abortion-pill policy. The White House withdrew her nomination this week as questions grew about whether she had enough Senate support.
Erik Baptist, senior vice president of legal strategy at Susan B. Anthony Pro-Life America, said the group had urged senators to delay consideration of Overton until the administration addressed two issues: mail-order access to abortion medication and the FDA’s review of the drug’s safety.
The group wants the next FDA nominee to end the mail-order policy introduced under the Biden administration and revise the agency’s approach to studying mifepristone, Baptist said.
Baptist argued that abortions have increased since the Supreme Court overturned Roe v. Wade, which he attributed to wider access to abortion drugs by mail. He said the group estimates that more than 15,000 abortions involving the drugs have occurred in states with abortion restrictions, making it difficult for those states to enforce their laws.
Under the Biden-era rules, mifepristone no longer had to be dispensed in person. Certified prescribers could provide prescriptions without an in-person visit, and certified pharmacies could send the medication through the mail.
Baptist also called for a new FDA study of mifepristone’s safety. He said the current review lacks important data and transparency about the agency’s methods, and does not adequately involve outside experts who have studied the drug.
He said a stronger review should be a broadly shared goal, arguing that more complete data, transparency and expert input would benefit the process regardless of political views.
Several anti-abortion organizations and Republican lawmakers have pressed the Trump administration to finish the FDA’s safety review and consider restoring restrictions. Some have called for taking mifepristone off the market. The FDA has said its review is underway, with results expected in December 2026 and a final report due by March 2027.
President Donald Trump selected Overton, a physician and White House adviser, in August to replace Marty Makary, who resigned in May. Kyle Diamantas has served as acting head of the agency since Makary’s departure.
Overton was previously vice chair and chief policy officer at the conservative America First Policy Institute. In a 2023 policy brief, she criticized the expansion of access to abortion pills.
The White House said it withdrew Overton’s nomination because she did not have enough support in Congress. Senate Health Committee Chair Bill Cassidy disputed that assessment, saying he believed she could have won approval both in committee and on the Senate floor. Cassidy, a Louisiana Republican, said he had been having productive discussions with senators.
Baptist said he was unsure whether the White House’s decision reflected concerns about anti-abortion lawmakers or other groups. He thought Cassidy had been making headway with the administration on the commitments his organization sought.
Cassidy had also questioned Overton’s support for Trump’s call to change the childhood vaccine schedule. He later said he was persuaded she was suitable for the FDA role after she promised to follow the science. Overton had appeared with Trump when he signed an order seeking changes to childhood vaccine recommendations, including separate measles, mumps and rubella shots once they became available in the United States.
At a September hearing, Cassidy said there was no scientific evidence for Trump’s suggestion that the combined MMR vaccine could be “quite lethal,” and warned the comment might discourage vaccination. Overton told him the vaccine was safe and effective.
Asked what she would do if Trump told her to set aside FDA safety standards, Overton said she would offer her best advice and comply with the legal requirements for reviewing products. Democratic senators Maggie Hassan of New Hampshire and Ed Markey of Massachusetts also questioned her about the vaccine and whether she would challenge the president. Overton again described the vaccine as safe and effective, and called it the best tool available during a measles outbreak.
Baptist said the next FDA commissioner should understand science and have experience running a large agency. He noted that the FDA has a complex bureaucracy and said knowledge of scientific research and drug approval would be important for the job.
He added that the administration need not wait for a new commissioner to act on abortion-pill policy. In his view, it already has the authority to make the changes his group is seeking, and the issue is whether officials are willing to use it.
Baptist also said changes to the safety study could be made immediately. Because the FDA expects to finish the review in December, he warned that officials should revise its methods before it is completed next year, even if the agency still has no confirmed commissioner.






